Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
P/E ratio for Altimmune, Inc. (ALT)
P/E ratio as of 2023: -6.77
According to Altimmune, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.77. At the end of 2022 the company had a P/E ratio of -9.11.
P/E ratio history for Altimmune, Inc. from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.77 |
| 2022 | -9.11 |
| 2021 | -3.93 |
| 2020 | -5.90 |
| 2019 | -1.21 |
| 2018 | -0.15 |
| 2017 | -0.55 |
| 2016 | 0.16 |
| 2015 | -8.26 |
| 2014 | -2.57 |
| 2013 | -1.92 |
| 2012 | -4.36 |
| 2011 | -5.53 |
| 2010 | -0.41 |
| 2009 | -0.38 |
| 2008 | -0.28 |
| 2007 | -0.31 |
| 2006 | 0.25 |
| 2005 | 12.60 |